New combo therapy targets Tough-to-Treat gut cancers
NCT ID NCT04430738
Summary
This study is testing whether adding a drug called tucatinib to standard cancer treatments is safe and effective for people with HER2-positive cancers of the digestive system, like stomach, colon, and gallbladder cancers. It involves about 40 participants who have advanced cancer that cannot be removed by surgery. The main goals are to find the safest dose and see if the drug combination helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, 464-8681, Japan
-
Barnes-Jewish Hospital
St Louis, Missouri, 63110, United States
-
Cancer Institute Hospital of Japanese Foundation for Cancer Research.
Koto-ku, Tokyo, 135-8550, Japan
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Duke University Medical Center, Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic Hospital
Phoenix, Arizona, 85054, United States
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
Osaka International Cancer Institute
Osaka, Osaka, 541-8567, Japan
-
PCM Trials
Denver, Colorado, 80218, United States
-
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
Siteman Cancer Center
St Louis, Missouri, 63108, United States
-
Siteman Cancer Center - North County
Florissant, Missouri, 63031, United States
-
Siteman Cancer Center - South County
St Louis, Missouri, 63129, United States
-
Siteman Cancer Center - St Peters
City of Saint Peters, Missouri, 63376, United States
-
Siteman Cancer Center - West County
Creve Coeur, Missouri, 63141, United States
-
St. Marianna University Hospital
Kawasaki, Kanagawa, 216-8511, Japan
-
University of Colorado Denver CTO(CTRC)
Aurora, Colorado, 80045, United States
-
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)
Aurora, Colorado, 80045, United States
-
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
Aurora, Colorado, 80045, United States
-
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, Colorado, 80045, United States
-
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, 87131, United States
-
University of Washington Medical Center
Seattle, Washington, 98195, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.